

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4856410

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CHENG LIU	11/07/2016
HONG LIU	11/07/2016
JINGYI XIANG	11/08/2016
SU YAN	11/09/2016
RECEIVING PARTY DATA	
Name:	EUREKA THERAPEUTICS, INC.
Street Address:	5858 HORTON STREET
Internal Address:	SUITE 362
City:	EMERYVILLE
State/Country:	CALIFORNIA
Postal Code:	94608
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15735133
CORRESPONDENCE DATA	
Fax Number:	(617)502-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-248-5000
Email:	patentdocket@choate.com
Correspondent Name:	CHOATE HALL & STEWART LLP
Address Line 1:	TWO INTERNATIONAL PLACE
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	2003080-1516
NAME OF SUBMITTER:	TRACY L. VRABLIK
SIGNATURE:	/Tracy L. Vrablik/
DATE SIGNED:	03/08/2018
Total Attachments: 18	
source=2003080-1516 executed Joint Assignment - Eureka#page1.tif	

source=2003080-1516 executed Joint Assignment - Eureka#page2.tif
source=2003080-1516 executed Joint Assignment - Eureka#page3.tif
source=2003080-1516 executed Joint Assignment - Eureka#page4.tif
source=2003080-1516 executed Joint Assignment - Eureka#page5.tif
source=2003080-1516 executed Joint Assignment - Eureka#page6.tif
source=2003080-1516 executed Joint Assignment - Eureka#page7.tif
source=2003080-1516 executed Joint Assignment - Eureka#page8.tif
source=2003080-1516 executed Joint Assignment - Eureka#page9.tif
source=2003080-1516 executed Joint Assignment - Eureka#page10.tif
source=2003080-1516 executed Joint Assignment - Eureka#page11.tif
source=2003080-1516 executed Joint Assignment - Eureka#page12.tif
source=2003080-1516 executed Joint Assignment - Eureka#page13.tif
source=2003080-1516 executed Joint Assignment - Eureka#page14.tif
source=2003080-1516 executed Joint Assignment - Eureka#page15.tif
source=2003080-1516 executed Joint Assignment - Eureka#page16.tif
source=2003080-1516 executed Joint Assignment - Eureka#page17.tif
source=2003080-1516 executed Joint Assignment - Eureka#page18.tif

COMBINED JOINT ASSIGNMENT & DECLARATION**A. ASSIGNMENT**

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
1. Cheng Liu	Emeryville, California
2. Hong Liu	El Sobrante, California
3. Jingyi Xiang	Walnut Creek, California
4. Su Yan	State College, Pennsylvania

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

**T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT
MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA; and**

☐ prepared for filing in the United States Patent and Trademark Office; or

☐ identified by United States Application Serial No. _____
filed in the United States Patent and Trademark Office on; _____; and

☒ identified by International Patent Application No. PCT/US2016/036735
filed on June 9, 2016; and

☒ and is also aware of the following priority applications:

Serial No.	Filed
62/173,330	June 9, 2015

WHEREAS, **Eureka Therapeutics, Inc.** (hereinafter "ASSIGNEE"), having a usual place of business at **5858 Horton Street, Suite 362, Emeryville, California 94608**, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us has sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. Our sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by each of us had this sale, assignment and transfer not been made;

AND, each of us hereby acknowledges that this Assignment, being of our entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, each of us hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts we know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, each of us further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct serial number(s) and/or filing date(s) into this assignment document, if appropriate;

AND, each of us hereby appoints ASSIGNEE as our common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, each of us hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, each of us covenants with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by us, and that full right to convey the same as herein expressed is possessed by us.

B. DECLARATION (37 CFR 1.63)

As below named inventors, we hereby declare that:

This declaration is directed to the patent application entitled:

**T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT
MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA; and**

☐ attached hereto or prepared for filing in the United States Patent and Trademark Office; or

☐ identified by United States Application Serial No. _____
filed in the United States Patent and Trademark Office on _____; or


☒ identified by International Patent Application No. PCT/US16/36735
filed on June 9, 2016.

The above-identified application was made or authorized to be made by us.

We believe that we are the original joint inventors of a claimed invention in the application.

We hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

We have reviewed and understand the contents of the application, including the claims and are aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Inventor Signature:  Date: 11/7/2016

Print Inventor Name: Cheng Liu

Address: 4 Commodore Drive, Unit D334
Emeryville, CA 94608

Eureka Ref.: ETI-2015-07-WO-PCT

Inventor Signature:  Date: Nov. 7. 2016

Print Inventor Name: Hong Liu

Address: 5573 Woodview Drive
El Sobrante, CA 94803

Inventor Signature: _____ Date: _____

Print Inventor Name: Jingyi Xiang


Address: 2170 San Luis Road
Walnut Creek, CA 94597

Inventor Signature: _____ Date: _____


Print Inventor Name: Su Yan

Address: 731 Partridge Lane
State College, PA 16803

Eureka Ref.: ETI-2015-07-WO-PCT


Witness Signature:  Date: Nov. 7, 2016

Print Witness Name: Diana Castillo

Witness Signature:  Date: Nov. 7, 2016

Print Witness Name: Mei Hong

The undersigned (whose title is supplied below) is authorized to sign on behalf of Eureka Therapeutics, Inc.

Signature:  Date: Nov 16, 2016

Name: Victor Shum

Title: General Counsel

COMBINED JOINT ASSIGNMENT & DECLARATION**A. ASSIGNMENT**

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
1. Cheng Liu	Emeryville, California
2. Hong Liu	El Sobrante, California
3. Jingyi Xiang	Walnut Creek, California
4. Su Yan	State College, Pennsylvania

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

**T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT
MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA; and**

☐ prepared for filing in the United States Patent and Trademark Office; or

☐ identified by United States Application Serial No. _____
filed in the United States Patent and Trademark Office on; _____; and

☒ identified by International Patent Application No. PCT/US2016/036735
filed on June 9, 2016; and

☒ and is also aware of the following priority applications:

Serial No.	Filed
62/173,330	June 9, 2015

WHEREAS, **Eureka Therapeutics, Inc.** (hereinafter "ASSIGNEE"), having a usual place of business at **5858 Horton Street, Suite 362, Emeryville, California 94608**, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us has sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. Our sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by each of us had this sale, assignment and transfer not been made;

AND, each of us hereby acknowledges that this Assignment, being of our entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, each of us hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts we know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, each of us further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct serial number(s) and/or filing date(s) into this assignment document, if appropriate;

AND, each of us hereby appoints ASSIGNEE as our common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, each of us hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, each of us covenants with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by us, and that full right to convey the same as herein expressed is possessed by us.

B. DECLARATION (37 CFR 1.63)

As below named inventors, we hereby declare that:

This declaration is directed to the patent application entitled:

**T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT
MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA; and**

☐ attached hereto or prepared for filing in the United States Patent and Trademark Office; or

☐ identified by United States Application Serial No. _____
filed in the United States Patent and Trademark Office on _____; or

☒ identified by International Patent Application No. PCT/US16/36735
filed on June 9, 2016.

The above-identified application was made or authorized to be made by us.

We believe that we are the original joint inventors of a claimed invention in the application.

We hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

We have reviewed and understand the contents of the application, including the claims and are aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Inventor Signature: _____ Date: _____

Print Inventor Name: Cheng Liu

Address: 4 Commodore Drive, Unit D334

Emeryville, CA 94608

Inventor Signature: _____ Date: _____

Print Inventor Name: Hong Liu

Address: 5573 Woodview Drive

El Sobrante, CA 94803

Inventor Signature:  Date: 11/08/2016

Print Inventor Name: Jingyi Xiang

Address: 2170 San Luis Road

Walnut Creek, CA 94597


Inventor Signature: _____ Date: _____

Print Inventor Name: Su Yan


Address: 731 Partridge Lane

State College, PA 16803

Eureka Ref.: ETI-2015-07-WO-PCT


Witness Signature:  Date: Nov. 8, 2016

Print Witness Name: Diana Castillo

Witness Signature:  Date: Nov. 8, 2016

Print Witness Name: Mei Hong

The undersigned (whose title is supplied below) is authorized to sign on behalf of Eureka Therapeutics, Inc.

Signature:  Date: Nov 16, 2016

Name: Victor Shum

Title: General Counsel

COMBINED JOINT ASSIGNMENT & DECLARATION**A. ASSIGNMENT**

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
1. Cheng Liu	Emeryville, California
2. Hong Liu	El Sobrante, California
3. Jingyi Xiang	Walnut Creek, California
4. Su Yan	State College, Pennsylvania

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

**T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT
MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA; and**

☐ prepared for filing in the United States Patent and Trademark Office; or

☐ identified by United States Application Serial No. _____
filed in the United States Patent and Trademark Office on; _____; and

☒ identified by International Patent Application No. PCT/US2016/036735
filed on June 9, 2016; and

☒ and is also aware of the following priority applications:

Serial No.	Filed
62/173,330	June 9, 2015

WHEREAS, **Eureka Therapeutics, Inc.** (hereinafter "ASSIGNEE"), having a usual place of business at **5858 Horton Street, Suite 362, Emeryville, California 94608**, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us has sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. Our sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by each of us had this sale, assignment and transfer not been made;

AND, each of us hereby acknowledges that this Assignment, being of our entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, each of us hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts we know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, each of us further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct serial number(s) and/or filing date(s) into this assignment document, if appropriate;

AND, each of us hereby appoints ASSIGNEE as our common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, each of us hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, each of us covenants with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by us, and that full right to convey the same as herein expressed is possessed by us.

B. DECLARATION (37 CFR 1.63)

As below named inventors, we hereby declare that:

This declaration is directed to the patent application entitled:

**T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT
MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA; and**

☐ attached hereto or prepared for filing in the United States Patent and Trademark Office; or

☐ identified by United States Application Serial No. _____
filed in the United States Patent and Trademark Office on _____; or

☒ identified by International Patent Application No. PCT/US16/36735
filed on June 9, 2016.

The above-identified application was made or authorized to be made by us.

We believe that we are the original joint inventors of a claimed invention in the application.

We hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

We have reviewed and understand the contents of the application, including the claims and are aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Inventor Signature: _____ Date: _____

Print Inventor Name: Cheng Liu

Address: 4 Commodore Drive, Unit D334

Emeryville, CA 94608

Inventor Signature: _____ Date: _____

Print Inventor Name: Hong Liu

Address: 5573 Woodview Drive


El Sobrante, CA 94803

Inventor Signature: _____ Date: _____

Print Inventor Name: Jingyi Xiang

Address: 2170 San Luis Road

Walnut Creek, CA 94597

Inventor Signature:  _____ Date: 11 / 09 / 2016

Print Inventor Name: Su Yan

Address: 731 Partridge Lane

State College, PA 16803


Witness Signature: J. Zuo Date: 11-9-2016

Print Witness Name: Zuo, Jia

Witness Signature: Lianwei Feng Date: 11-9-2016

Print Witness Name: Lianwei Feng

The undersigned (whose title is supplied below) is authorized to sign on behalf of Eureka Therapeutics, Inc.

Signature:  Date: 11/16/2016

Name: Victor Shum

Title: General Counsel